A Phase 1, Open-label, Randomized, Parallel-group Study in Healthy Subjects to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Rilpivirine (Primary) ; Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 08 Aug 2018 Status changed from recruiting to completed.
- 18 May 2017 Status changed from not yet recruiting to recruiting.
- 27 Apr 2017 New trial record